A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

Published: Dec 1, 2019
Abstract
Metastatic prostate cancer, which presents as either null de novo null (4–5% of cases) or as a recurrence following definitive therapy for localized disease, has historically been treated with androgen deprivation therapy (ADT) alone. Although 90% of men initially respond to ADT, almost all eventually become castration-resistant and develop progression of their...
Paper Details
Title
A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer
Published Date
Dec 1, 2019
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.